Caris Life Sciences (CAI) Non-Current Debt (2024 - 2026)

Caris Life Sciences has reported Non-Current Debt for 3 years, with the latest figure at $393.0 million in Q2 2026.

• On a quarterly basis, Non-Current Debt rose 5.18% year-over-year to $393.0 million in Q2 2026; TTM through Jun 2026 was $393.0 million, a 5.18% increase from a year earlier, with the FY2025 full-year figure at $378.8 million, up 1.52% from the prior year.
• Non-Current Debt was $393.0 million for Q2 2026 at Caris Life Sciences, up from $381.4 million in the prior quarter.
• The five-year high for Non-Current Debt was $393.0 million in Q2 2026, with the low at $373.1 million in Q4 2024.
• Average Non-Current Debt over 3 years is $379.4 million, with a median of $377.6 million recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Non-Current Debt increased 1.52% in 2025, then climbed 5.18% in 2026.
• Over 3 years, Non-Current Debt stood at $373.1 million in 2024, then increased by 1.52% to $378.8 million in 2025, then advanced by 3.74% to $393.0 million in 2026.
• The last three Non-Current Debt figures came in at $393.0 million (Q2 2026), $381.4 million (Q1 2026), and $378.8 million (Q4 2025), per Business Quant data.